views
![Postmenopausal Osteoporosis Market Growth Accelerated by Rising Demand for Bone Health Medications](https://s3.us-west-2.amazonaws.com/timessquarereporter.com/upload/media/posts/2024-01/12/postmenopausal-osteoporosis-market-growth-accelerated-by-rising-demand-for-bone-health-medications_1705059084-b.jpg)
Postmenopausal osteoporosis occurs in women after menopause when estrogen levels drop sharply. It is a condition that weakens bones and makes them fragile. Medications such as bisphosphonates, estrogen therapy, selective estrogen receptor modulators, and monoclonal antibodies are prescribed by physicians to treat osteoporosis and prevent fractures.
The global Postmenopausal Osteoporosis Market is estimated to be valued at US$ 4747.9 Mn in 2023 and is expected to exhibit a CAGR of 67. % over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The rising demand for bone health medications is one of the key trends driving the growth of the postmenopausal osteoporosis market. As more women are diagnosed with osteoporosis after menopause, the consumption of medications such as bisphosphonates and selective estrogen receptor modulators has been increasing steadily. These drugs not only help strengthen bones but also reduce the risk of fractures caused by osteoporosis. Manufacturers are also focusing on developing novel medications with improved efficacy and safety profiles which is anticipated to further fuel the market growth over the forecast period.
Segment Analysis
The global postmenopausal osteoporosis market is dominated by the bisphosphonates sub segment due to its higher efficacy and safer side effect profile compared to other available drugs in the market. Bisphosphonates directly inhibit bone resorption by binding to calcium phosphate crystals in the bone, and also induce apoptosis in osteoclasts.
Key Takeaways
Global Postmenopausal Osteoporosis Market Size is expected to witness high growth.
Regional analysis: North America is projected to retain highest market share during the forecast period owing to rising prevalence of postmenopausal osteoporosis along with bone-related disorders, strong presence of major pharmaceutical companies and launch of novel therapeutics. According to National Osteoporosis Foundation, nearly 10 million individuals are affected by osteoporosis and low bone mass.
Key players operating in the postmenopausal osteoporosis market are focused on introducing technologically advanced medicines with enhanced efficacy and fewer side effects. For instance, in 2019, IBM Research, Inc launched Hybrid Classical–Quantum Neural Network for Drug Discovery for postmenopausal osteoporosis.
Get More Insights on this Topic- https://www.marketwebjournal.com/postmenopausal-osteoporosis-market-share-size-and-demand/
![disclaimer](https://www.timessquarereporter.com/disclaimer-timessquarereporter.jpg)
Comments
0 comment